Oral deferasirox may be an effective iron chelator in patients with thalassaemia and transfusional iron overload

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1387, 2003-01, pp. : 6-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload

By Cappellini MD   Taher A  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 13, 2008-09 ,pp. : 2391-2402

Informa Healthcare

Access to resources Recommend Favorite

Deferasirox: A Review of its Use in the Management of Transfusional Chronic Iron Overload

By Yang Lily P.H.   Keam Susan J.   Keating Gillian M.  

Drugs, Vol. 67, Iss. 15, 2007-01 ,pp. : 2211-2230

Adis International

Access to resources Recommend Favorite

Deferasirox: a guide to its use in transfusional chronic iron overload

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 24, Iss. 2, 2008-02 ,pp. : 1-4

Adis International

Access to resources Recommend Favorite

Deferasirox dominates deferoxamine for iron overload

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 665, 2012-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Deferasirox a strong contender for iron overload in all ages

By  

Inpharma, Vol. 1, Iss. 1476, 2005-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite